Key result
Higher intrathoracic impedance thresholds (>30 Ω-days) were significantly associated with 1.48 to 2.24 more ventricular arrhythmia episodes compared to 0-30 Ω-days in heart failure patients.
Why the study?
Does higher intrathoracic impedance (OptiVol threshold) predict episodes of ventricular arrhythmias in patients with HFrEF?
Cohort (n=87)
Does higher intrathoracic impedance (OptiVol threshold) predict episodes of ventricular arrhythmias in patients with HFrEF?
Increases in intrathoracic impedance are significantly associated with a higher number of ventricular arrhythmia episodes in patients with heart failure with reduced ejection fraction.
May flag higher VA risk in HFrEF via OptiVol; hypothesis-generating for impedance-guided monitoring, needs prospective validation.
BACKGROUND: Ventricular arrhythmias (VAs) are independently related to mortality risk in patients with heart failure (HF). The wide availability of implantable cardioverter defibrillators and cardiac resynchronization therapy devices now offers an opportunity to clinically correlate the two disease processes. We hypothesized that there is an association between changes in the intrathoracic impedance and episodes of VA. METHODS: Nonconcurrent prospective study of adults (age >20 years) with known HF with reduced ejection fraction (<35%). The OptiVol threshold was categorized as follows: 0-30 Ω-days, 31-60 Ω-days, 61-90 Ω-days, 91-120 Ω-days, and >120 Ω-days. Patients with OptiVol values at 0-30 Ω-days were used as the reference group. Receiver operating characteristic analysis was used to estimate the sensitivity and specificity at each threshold. RESULTS: Of the 87 eligible patients, 65.5% were males. The mean age of the sample was 73.3 years (±12.7). Compared to patients in the 0-30 Ω-days category, those in the 31-60, 61-90, 91-120, and >120 Ω-days groups had, on average, 1.48, 1.64, 2.24, and 1.6 more VAs, respectively (P = 0.002, 0.009, 0.010 and 0.009, respectively). The sensitivity and specificity of each threshold were as follows: 82.6% and 61.7% at 31-60 Ω-days, 43.5% and 78.3% at 61-90 Ω-days, 30.4% and 85.0% at 91-120 Ω-days, and 21.7% and 88.3% at >121 Ω-days. CONCLUSION: Our study found a significant positive relationship between changes in intrathoracic impedance and episodes of VAs in patients with HF.
No takes yet. Share an insight, caveat, or question.
Osman et al. (2018) conducted a cohort in Heart failure with reduced ejection fraction (n=87). Intrathoracic impedance (OptiVol threshold) vs. 0-30 Ω-days was evaluated on Episodes of ventricular arrhythmias (p=0.002, 0.009, 0.010, 0.009). Higher intrathoracic impedance thresholds (>30 Ω-days) were significantly associated with 1.48 to 2.24 more ventricular arrhythmia episodes compared to 0-30 Ω-days in heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: